Navigation Links
Xytis Names Gordon H. Busenbark as Chief Financial Officer
Date:10/19/2007

IRVINE, Calif., Oct. 19 /PRNewswire/ -- Xytis Inc., a privately held biotechnology company focused on developing novel therapeutics to treat central nervous system (CNS) diseases, today announced that Gordon H. Busenbark has joined the company as Chief Financial Officer. Mr. Busenbark has more than 25 years of experience in the pharmaceutical, biotechnology and medical devices industries. During a 23 year career at Baxter Healthcare, Mr. Busenbark held a number of senior-level financial, operational and general management positions in both the U.S. and Europe. This included roles as Chief Financial Officer of Immuno AG when the company was acquired by Baxter, and President of Baxter's global Plasma Therapeutics business. Mr. Busenbark's most recent role was as Chief Financial Officer at Encysive Pharmaceuticals, where his accomplishments included raising more than $100 million in debt and equity financing.

"We are very pleased to have Gordon join Xytis," said Vincent F. Simmon, CEO and President. "He brings great financial and operational experience, both from a large pharmaceutical company perspective as well as from that of a smaller biotechnology company. Gordon joins us at an exciting time for Xytis. Our Phase 2 clinical trial in Traumatic Brain Injury (TBI) is approximately half way enrolled. Also, there is considerable partnering interest in two of our pre-clinical programs; positive allosteric modulators of GABA-A receptor and of alpha-7 nicotinic acetylcholine receptors. His experience and assistance in financing and marshalling these programs forward will be greatly welcomed."

Mr. Busenbark has both a B.S. in Accounting and an MBA from the University of Utah.

About Xytis

Xytis Inc. is a privately held discovery and development biopharmaceutical company, headquartered in Irvine, California, and having a clinical development group in Nyon, Switzerland, focused on innovative CNS drug candidates. The Company's investors include At
'/>"/>

SOURCE Xytis Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BETHESDA, Md. , Sept. 16, 2014 ... a biotechnology company developing DCVax® personalized immune therapies for ... the first product to receive formal designation as a ... to Medicines Scheme" (EAMS) launched in the UK in ... a 2-step process for early access approval under the ...
(Date:9/16/2014)... Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. (Nasdaq: ... to delivering high quality and novel medicines to physicians ... Executive Officer Mark Baum will be a ... Select Conference in New York City.  Mr. Baum will ... Dropless™ campaign in ophthalmology. The presentation is scheduled for ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Henry Schein To Present At The Leerink Partners Services Roundtable 2
(Date:9/16/2014)... (PRWEB) September 16, 2014 Cloud ... Live Streaming (HLS) & UStream API’S to serve m3u8 ... wonderful feature for broadcasting live video events with hundreds ... apps. , The App Builder is known for making ... android, iOS, BlackBerry and Windows 8 and already over ...
(Date:9/16/2014)... Wholelifeinsurancecompanies.org has released a new ... with a bad heart condition. , Clients who have ... insurance if they compare quotes. Most agencies will insure ... on the actual and past medical condition. , ... heart attacks in the past, his or her chances ...
(Date:9/16/2014)... An experimental positron emission tomography (PET) tracer is effective ... still alive, according to a case study conducted at ... at Molecular Neuroimaging (MNI) LLC in New Haven, and ... . , Specifically, the study results suggest that an ... to latch onto a protein called tau that accumulates ...
(Date:9/16/2014)... predict a man,s risk of getting prostate cancer after ... analysis of the cancer,s genetic biomarkers, reported in ... and Biomedical Innovation,s Dr Jyotsna Batra and Distinguished Professor ... large consortia of research hubs around the world, said ... in 80,000 men. , "It,s the largest analysis of ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 An experimental ... concussion-related brain disease while a person is still alive, ... School of Medicine at Mount Sinai, and at Molecular ... 16 in the journal Translational Psychiatry. , Specifically, the ... [18 F]-T807, which is designed to latch onto a ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:New gene research helps pinpoint prostate cancer risk 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4
... province said the SARS virus could be stopped and could ... health department, said the average daily new cases had dropped ... He gave this assurance as he was treating three foreigners, ... were infected.// ,He said the number of cases of ...
... 2003 Annual Meeting of the American Association for Cancer Research, ... means of cancer prognosis than measuring body mass index and ... the measures for detecting breast cancer are perfect, says lead ... ,But, he says that levels of leptin which signals ...
... St Mary's Hospital, Manchester, UK, has shown that family history of ... breast cancer. A survey of a group of 99 women under ... third of them had a strong history of either breast or ... cancer, 44 per cent were found to carry// mutations in the ...
... Kansas have now studied a new electrical device,that ... victims of Parkinson's disease.,This new treatment involves implanting ... of life for Parkinson's patients. This,electrical device helps ... the,signals that otherwise cause disabling tremor. The researchers ...
... long time now a lot of health experts that to ... has been advised we should,drink at least eight 8-ounce glasses ... Researchers from Center for Human Nutrition at the,University of Nebraska ... keep ourselves hydrated.// A group of 27 male volunteers were ...
... the A & A Pain Institute in St Louis, Missouri(A ... of pain), have,found that an anticonvulsant drug levetiracetam brings dramatic ... seven patients between 39 and 67 who had,severe nerve pain ... on,the nerve, analgesic drugs were not effective in relieving the ...
Cached Medicine News:
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
... The LightCycler 2.0 System is the ... Applied Science. This new instrument offers six ... 530, 560, 610, 640, 670, and 710nm. ... cooling by air and working with glass ...
Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
Medicine Products: